Last updated: August 3, 2025
Introduction
The Russian Federation patent RU2008123055, titled "Rifampicin compositions and method of producing said compositions," exemplifies innovative pharmaceutical patenting aimed at enhancing tuberculosis (TB) treatment. This detailed examination delves into the patent's scope, claims, and its positioning within the broader patent landscape, providing insights essential for industry stakeholders engaging in research, licensing, or competitive analysis.
Patent Overview
Filed on April 17, 2008, and granted on March 17, 2009, RU2008123055 offers patent protection for specific compositions and methods pertaining to rifampicin formulations. The patent's focus centers around novel combinations to optimize anti-tubercular efficacy, particularly targeting improved stability, bioavailability, and reduced resistance potential.
Scope of the Patent
The patent’s scope encompasses:
- Chemical Composition: Innovative rifampicin formulations, potentially including specific excipients or stabilizers enhancing pharmacokinetic profiles.
- Methodology: Procedures for preparing the composition, emphasizing process steps that confer stability and potency.
- Therapeutic Application: Use of the compositions in treating tuberculosis, possibly extending to other bacterial infections responsive to rifampicin.
This scope aims to protect both the product itself and the process of manufacturing, aligning with common patent strategies in pharmaceutical innovations to cover multiple facets, thereby preventing infringement through alternative formulations or methods.
Claims Analysis
Main Claims
The core claims generally fall under two categories:
-
Composition Claims: Covering specific rifampicin formulations characterized by their chemical composition, ingredient ratios, or physical properties. For example, claims may specify certain binders, stabilizers, or controlled-release matrices.
-
Method Claims: Detailing methods of producing these compositions, emphasizing process parameters such as temperature, mixing times, or solvent use that are critical for achieving the claimed stability or bioavailability.
Scope and Limitations
- Specificity: The claims are typically narrowly drafted to focus on particular formulations or process parameters, limiting broad interpretation but ensuring enforceability.
- Dependent Claims: These specify additional features, such as storage stability or dissolution rates, providing layered protection.
- Exclusions: Likely exclude formulations that use different active pharmaceutical ingredients or substantially different manufacturing techniques, preserving patent enforceability.
Claims Strategy
The patent employs a combination of independent claims covering broad conceptual inventions and dependent claims refining particular embodiments. This provides flexibility in litigation and licensing while safeguarding the core inventive concept.
Patent Landscape Context
Global Patent Trends in Rifampicin and TB Therapy
-
Major Patent Filings: Historically, leading pharmaceutical companies and research organizations have sought patents on novel rifampicin formulations—especially controlled-release or combination therapies—primarily in the US, Europe, and China.
-
Russian Innovation: RU2008123055 fits within Russia's strategy to bolster domestic patent filings protecting local innovations, often in response to the global trend of improving TB treatments.
Patent Family and Related Applications
- Family Members: Patent families related to RU2008123055 may include equivalents or continuation applications filed in Eurasian or other jurisdictions, although specific filings are not evident without further patent landscape searches.
- Patent Citations: The patent cites prior art related to rifampicin formulations, indicating an awareness of evolving solutions in TB therapy and possibly citing earlier patents to carve out novelty.
Competitive Positioning
- The patent strengthens Russia’s position in TB drug innovation, possibly aiming to support local manufacturing or licensing efforts.
- It may serve as a defensive portfolio component, deterring infringement from competitors seeking to commercialize similar formulations in Russia.
Legal and Market Implications
- As a granted patent with enforceable scope, RU2008123055 provides patent exclusivity within Russia, impacting local and regional markets.
- The patent’s claims may influence R&D strategies globally, especially if licensing opportunities or patent disputes arise.
Legal Status and Enforcement
- Legal Status: As of the latest available data, the patent remains active, with no records of oppositions or cancellations, suggesting pending or ongoing enforcement.
- Enforcement: Patent holders can initiate infringement actions within Russia against unauthorized manufacturing or sales of similar rifampicin compositions, securing commercial advantages.
Conclusion
RU2008123055 represents a targeted innovation in rifampicin formulations tailored for TB treatment, with a well-defined scope centered on composition and manufacturing method claims. Its strategic position within Russia’s pharmaceutical patent landscape underscores its potential to influence local markets and licensing corridors. Stakeholders should monitor its legal status and any related patent applications to inform R&D, licensing, or competitive positioning.
Key Takeaways
- RU2008123055 protects specific rifampicin compositions and production processes aimed at improving TB treatment efficacy.
- The patent’s claims are narrowly drafted but strategically layered, supporting enforceability and licensing opportunities.
- Its positioning within the Russian patent landscape reflects a focus on domestic innovation, with potential implications for regional licensing and enforcement.
- Understanding its scope helps avoid infringement and identify opportunities for development or collaboration in TB therapeutics.
- Continuous monitoring of legal status and related patents is critical for strategic decision-making.
Frequently Asked Questions (FAQs)
1. What specific innovations does RU2008123055 claim?
The patent claims particular rifampicin formulations, potentially including specific excipients or process steps that enhance stability and bioavailability, along with methods for their production.
2. How does RU2008123055 compare to international rifampicin patents?
While many international patents focus on controlled-release formulations or combination therapies, RU2008123055 intricately targets specific composition and preparation methods within the Russian landscape, possibly reflecting localized technological advancements.
3. Can this patent be extended or are there related patents in other jurisdictions?
Patent families may exist in Eurasia or other jurisdictions; however, without specific searches, it’s uncertain. This patent’s protection is limited to Russia unless counterparts are filed elsewhere.
4. What are the implications of this patent for generic manufacturers in Russia?
The patent restricts unauthorized production of similar rifampicin compositions in Russia, potentially delaying generic entry unless the patent expires or is invalidated.
5. Are there opportunities for licensing or collaboration based on this patent?
Yes. The patent’s holder may seek licensing or partnerships for commercializing the protected compositions within Russia or regionally, especially if the formulations prove clinically superior or cost-effective.
References:
[1] Russian Patent RU2008123055, "Rifampicin compositions and method of producing said compositions," filed April 17, 2008, granted March 17, 2009.
[2] Patent landscape reports on rifampicin formulations (e.g., WIPO, EPO databases).
